Singlera Genomics Raises $150 Million in Series B Financing

Singlera Genomics Raises $150 Million in Series B Financing

San Diego and Shanghai, China-based Singlera Genomics today a $150 million Series B financing round that will help the company expand its early cancer screening research and development efforts. The round was led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment. Addditional investors include Huamei International, Linden Asset Group, Wuxi Capital, FutureX Skyline Capital, Shanghai Free Trade Zone Fund, and initial investors from the Series A round such as Greenpine Capital, Prosperico Ventures, and Proxima Ventures joined with follow-on investment.

Founded in 2014, Singlera has focused its efforts on non-invasive early screening of cancer leveraging its patented methylation detection technology for early tumor diagnosis and cancer prevention.

I am honored that the innovative R&D, clinical transformation, and commercialization capabilities of Singlera have been recognized by top investors,” notes Johny Zhang, company co-founder and CEO, in a prepared statement. “Singlera has been aiming to overcome early cancer screening and diagnosis. It has made a series of major breakthroughs in cancer early screening and early diagnostic technology. The next priority is to accelerate the commercialization of products so that these innovations can be applied to cancer prevention and treatment for hundreds of millions of people.”

Earlier this year, Singlera, in collaboration with researchers at Fudan University published research results, which validated the early cancer detection capabilities of Singlera’s circulating tumor DNA (ctDNA) methylation multi-cancer screening technology, called PanSeer. Using funds from the new round of financing, Singlera will continue to carry out large-scale pan-cancer early screening prospective studies.

“Singlera has been committed to building an open and diversified ‘industry-university-research-medicine’ collaborative innovation ecosystem. In the past few years, we have cooperated with dozens of domestic and international scientific research institutes, hospitals and Pharmaceutical companies have carried out extensive cooperation, which has laid a huge advantage for us in basic research and application results transformation of early tumor screening and liquid biopsy,” Professor Yuan Gao, co-founder and scientific advisor of Singlera, said in a statement. “We have developed early cancer screening and diagnostic technologies and products covering a variety of cancer types including lung, colorectal, liver, stomach, esophageal, pancreatic, and thyroid. This round of financing will help us carry out large-scale prospective studies and clinical trials”.